{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:35:04Z","timestamp":1789547704378,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ijcard.2018.06.093","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T01:10:32Z","timestamp":1530061832000},"page":"348-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction"],"prefix":"10.1016","volume":"274","author":[{"given":"Thor","family":"Ueland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Kleveland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika E.","family":"Michelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune","family":"Wiseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Kristian","family":"Dam\u00e5s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten B.","family":"Holven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l","family":"Aukrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Gullestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Yndestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2018.06.093_bb0005","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.phrs.2017.02.001","article-title":"Lipoprotein(a) and inflammation: a dangerous duet leading to endothelial loss of integrity","volume":"119","author":"Pirro","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ijcard.2018.06.093_bb0010","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.06.093_bb0015","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2018.06.093_bb0020","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O'Donoghue","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.06.093_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014328","article-title":"Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases","volume":"5","author":"Schultz","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2018.06.093_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2017.02.018","article-title":"Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: results from the CARdiovascular in rheuMAtology study project","volume":"11","author":"Garcia-Gomez","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.ijcard.2018.06.093_bb0035","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/annrheumdis-2015-207872","article-title":"Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis","volume":"75","author":"Gabay","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ijcard.2018.06.093_bb0040","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ijcard.2018.06.093_bb0045","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/clc.4960241103","article-title":"Interleukin-6 and acute coronary syndrome","volume":"24","author":"Ikeda","year":"2001","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2018.06.093_bb0050","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.06.093_bb0055","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1399-0004.1994.tb04408.x","article-title":"Changes in Lp(a) lipoprotein and other plasma proteins during acute myocardial infarction","volume":"46","author":"Andreassen","year":"1994","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ijcard.2018.06.093_bb0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/00365519209088771","article-title":"Lipoprotein(a) and acute-phase proteins in acute myocardial infarction","volume":"52","author":"Slunga","year":"1992","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.ijcard.2018.06.093_bb0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0021-9150(89)90218-9","article-title":"Transient changes of serum lipoprotein(a) as an acute phase protein","volume":"78","author":"Maeda","year":"1989","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2018.06.093_bb0070","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.003012","article-title":"Lipoprotein(a) interactions with low-density lipoprotein cholesterol and other cardiovascular risk factors in premature acute coronary syndrome (ACS)","volume":"5","author":"Afshar","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2018.06.093_bb0075","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1136\/annrheumdis-2013-204933","article-title":"Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox","volume":"73","author":"Gonzalez-Gay","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ijcard.2018.06.093_bb0080","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1136\/annrheumdis-2017-211708","article-title":"Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis","volume":"76","author":"Robertson","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ijcard.2018.06.093_bb0085","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/480784","article-title":"A systematic literature review of the association of lipoprotein(a) and autoimmune diseases and atherosclerosis","volume":"2012","author":"Missala","year":"2012","journal-title":"Int. J. Rheumatol."},{"key":"10.1016\/j.ijcard.2018.06.093_bb0090","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","article-title":"Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium","volume":"38","author":"Waldeyer","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.06.093_bb0095","doi-asserted-by":"crossref","first-page":"481","DOI":"10.33549\/physiolres.930511","article-title":"Gender differences in plasma levels of lipoprotein (a) in patients with angiographically proven coronary artery disease","volume":"53","author":"Frohlich","year":"2004","journal-title":"Physiol. Res."},{"key":"10.1016\/j.ijcard.2018.06.093_bb0100","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/jama.296.11.1363","article-title":"Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women","volume":"296","author":"Suk Danik","year":"2006","journal-title":"JAMA"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318322587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318322587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T10:47:29Z","timestamp":1693738049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527318322587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":20,"alternative-id":["S0167527318322587"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.06.093","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.06.093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}